Deric L. Wheeler - Concepedia

Author

Deric L. Wheeler

Also Known As

D L Wheeler, D Wheeler, D. L. Wheeler, D. Wheeler, D.L. Wheeler, Deric L Wheeler, Deric L. Wheeler, Deric Wheeler, Joseph Ghanime López, Wheeler, Deric L.

244

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

University of Wisconsin–Madison University of Wisconsin Carbone Cancer Center University of Chicago City of Hope Wisconsin Institutes for Discovery

About

Deric L. Wheeler is an author at University of Wisconsin–Madison specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	28	2.4K
2	Cell Biology	19	22	1.6K
3	Health Sciences	3	3	119
4	Allergy	1	1	537
5	Biomedical Engineering	1	1	40

Deric L. Wheeler

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members Deric L. Wheeler, Shih‐Hao Huang, Tim J. Kruser, Oncogene Drug Resistance AnalysisAllergyFamily MembersPathogenesisPathology	2008	537
Nuclear EGFR contributes to acquired resistance to cetuximab C Li, Mari Iida, Emily Dunn, Oncogene Tumor BiologyMedicineNuclear EgfrCancer GeneticsCancer Biology	2009	308
AXL Mediates Resistance to Cetuximab Therapy Toni M. Brand, Mari Iida, Andrew P. Stein, Cancer Research ImmunologyEgfr Antibody CetuximabPharmacotherapyTumor BiologyPositive Feedback Loop	2014	191
Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma Hiromitsu Hatakeyama, Haixia Cheng, Pamela S. Wirth, PLoS ONE	2010	158
Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab Deric L. Wheeler, Mar Iida, Tim J. Kruser, Cancer Biology & Therapy Egfr ExpressionSignal TransductionSignaling PathwayMedicineReceptor Tyrosine Kinase	2009	149
Activation of Multiple ERBB Family Receptors Mediates Glioblastoma Cancer Stem-like Cell Resistance to EGFR-Targeted Inhibition Paul A. Clark, Mari Iida, Daniel M. Treisman, Neoplasia	2012	130
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab Emily Dunn, Mari Iida, Rebecca A. Myers, Oncogene Gastrointestinal OncologyMedicineColorectal CancerPathologyOncology	2010	129
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma Toni M. Brand, Mari Iida, Andrew P. Stein, Clinical Cancer Research	2015	117
p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation Shyhmin Huang, Sergi Benavente, Eric A. Armstrong, Cancer Research Functional P53Tumor MicroenvironmentOncogenic AgentMedicineGrowth Factor Receptor	2011	112
An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy Jiyoon Bu, Ashita Nair, Mari Iida, Nano Letters	2020	112

Page 1